Correspondence 0001213900-23-009270 from Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Ltd.
Date: Feb. 8, 2023 · CIK: 0001536196 · Accession: 0001213900-23-009270

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-269485

Date

Feb. 8, 2023

Author

Pnina Fishman, Ph.D.

Form

CORRESP

Company

Can-Fite BioPharma Ltd.

Letter

Can-Fite BioPharma Ltd.

Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

February 8, 2023

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Can-Fite BioPharma Ltd.

Registration Statement on Form F-1

File No. 333-269485

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-269485) of the Company (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:30 p.m., Eastern Time, on February 10, 2023 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling Gary Emmanuel at (212) 801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

Very truly yours,
CAN-FITE BIOPHARMA LTD.

Show Raw Text

CORRESP
1
filename1.htm

Can-Fite
BioPharma Ltd.

10
Bareket Street

Kiryat
Matalon, P.O. Box 7537

Petach-Tikva
4951778, Israel

February
8, 2023

Securities
and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    Can-Fite BioPharma Ltd.

    Registration
    Statement on Form F-1

    File
    No. 333-269485

VIA
EDGAR

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Can-Fite BioPharma Ltd. (the “Company”) hereby respectfully
requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-269485) of the Company (the “Registration
Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:30 p.m., Eastern Time,
on February 10, 2023 or as soon thereafter as may be practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, P.A., by calling Gary Emmanuel at (212) 801-9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw
this request for acceleration.

    Very truly yours,

    CAN-FITE BIOPHARMA LTD.

    By:
    /s/ Pnina Fishman, Ph.D.

    Name:
    Pnina Fishman, Ph.D.

    Title:
    Chief Executive Officer

cc:
Gary Emmanuel (Greenberg Traurig, P.A.)

SecProbe.io